the Second Affiliated Hospital of Zhejiang University School of Medicin
Welcome,         Profile    Billing    Logout  
 5 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Wen
NCT04171180: The Efficacy of Budesonide/Formoterol in Cough Variant Asthma

Recruiting
4
500
RoW
budesonide/formoterol
Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Tongji Hospital, Tongji University School of Medicine, Tongji Hospital, Zunyi Medical College, Central South University, China-Japan Friendship Hospital, Shenzhen People's Hospital
Cough Variant Asthma
09/20
05/23
ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting
4
364
RoW
Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline
Shanghai Pulmonary Hospital, Shanghai, China
Bronchiectasis Adult, Pseudomonas Aeruginosa Infection
10/25
12/25
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
NCT03713879: Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

Recruiting
3
1734
RoW
pancreatic stenting, Indomethacin, indocid
Chinese University of Hong Kong, Xijing Hospital, Changhai Hospital, Tianjin Union Medical Center, Zhejiang University, Eastern Hepatobiliary Surgery Hospital
Post ERCP Pancreatitis
12/25
12/25
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting
3
756
Europe, US, RoW
Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
07/27
07/29
NCT05582278: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Recruiting
2
60
RoW
D-TACE, D-TACE+lenvatinib+tislelizumab, HAIC, HAIC+Lenvatinib+tislelizumab, Lenvatinib, Targeted therapy, tislelizumab, PD-1 inhibitors
Wen Li
Unresectable Hepatocellular Carcinoma
01/24
01/24
NCT03670446: Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants：A Study on Behavioral Patterns

Recruiting
N/A
400
RoW
Pharmacists' intervention
Cui Yimin
Anticoagulants, Intention, Behavioral Symptoms
10/23
12/23
NCT05442125: First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization

Recruiting
N/A
1146
RoW
Using DNA methylome to select embryos, Using morphologic score to select embryos
Shandong University, RenJi Hospital, Reproductive & Genetic Hospital of CITIC-Xiangya, Nanjing Maternity and Child Health Care Hospital, ShangHai Ji Ai Genetics & IVF Institute, Suzhou Municipal Hospital, The First Hospital of Jilin University, Sir Run Run Shaw Hospital, The Affiliated Hospital Of Guizhou Medical University, The Second Hospital of Hebei Medical University, Third Affiliated Hospital of Zhengzhou University, Ruijin Hospital, International Peace Maternity and Child Health Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Hainan Medical University, The First Affiliated Hospital of Anhui Medical University, Fujian Maternity and Child Health Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital with Nanjing Medical University, 900 th Hospital of Joint Logistics Support Force, Guangzhou Womenand Children's Medical Center, Changhai Hospital, Shenzhen Maternity & Child Healthcare Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Jining Medical University, Siriraj hospital, Mahidol university, Thailand
Reproductive Techniques, Assisted, DNA Methylation
06/24
05/25
NCT05763758: Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain

Not yet recruiting
N/A
200
US
No intervention
Massachusetts General Hospital, Florida State University
Experimental Pain, Low Back Pain
10/24
12/24
NCT05895006: A Neurosensory Account

Recruiting
N/A
160
US
alpha-frequency tACS, Random noise stimulation
Florida State University
Post Traumatic Stress Disorder
05/26
10/27
Shen, Huahao
NCT04171180: The Efficacy of Budesonide/Formoterol in Cough Variant Asthma

Recruiting
4
500
RoW
budesonide/formoterol
Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Tongji Hospital, Tongji University School of Medicine, Tongji Hospital, Zunyi Medical College, Central South University, China-Japan Friendship Hospital, Shenzhen People's Hospital
Cough Variant Asthma
09/20
05/23
NCT05596721: Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma

Not yet recruiting
4
248
RoW
Azithromycin, ICS/LABA
Second Affiliated Hospital, School of Medicine, Zhejiang University
Asthma, Chest Syndrome, Azithromycin, Effect of Drug
03/24
03/24
STEP, NCT06465485: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

Recruiting
3
500
RoW
Benralizumab, Fasenra
AstraZeneca
Severe Eosinophilic Asthma
10/25
08/26
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT05979051: A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Recruiting
2/3
112
RoW
SHR-1703, SHR-1703 Placebo
Guangdong Hengrui Pharmaceutical Co., Ltd
Eosinophilic Granulomatosis With Polyangiitis
03/26
05/27
EC-CPHS, NCT05028985: Early COPD for China Pulmonary Health Study Stage II

Recruiting
N/A
400
RoW
China-Japan Friendship Hospital, Chinese Academy of Medical Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Capital Medical University, Peking University Third Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Obstructive Pulmonary Disease
01/25
12/25

Download Options